United Therapeutics
$541.70Change from previous close: −5.19%Absolute change: −$29.68
At a glance
- Revenue growth
- +10.61%
- 2025 vs 2024
- Net income growth
- +11.68%
- 2025 vs 2024
- Net margin
- 41.9%
- 2024: 41.5%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Total assets | 7,220 | 6,714 | 7,880 | 7,351 | 7,908 | — |
| Current assets | 3,484 | 2,872 | 3,703 | 3,494 | 3,827 | — |
| Cash and equivalents | 1,803 | 1,280 | 1,557 | 1,340 | 1,593 | — |
| Short-term investments | 859 | 874 | 1,363 | 1,428 | 1,456 | — |
| Receivables | 310 | 312 | 350 | 298 | 379 | — |
| Inventory | 194 | 178 | 183 | 177 | 169 | — |
| Net property, plant and equipment | 1,930 | 1,841 | 1,730 | 1,556 | 1,362 | — |
| Goodwill | — | — | 32.3 | — | — | — |
| Other intangible assets | — | — | 84.2 | — | — | — |
| Long-term investments | 1,141 | 1,317 | 1,777 | 1,567 | 1,918 | — |
| Current liabilities | 608 | 599 | 561 | 546 | 527 | — |
| Accounts payable | — | — | 7.1 | — | — | — |
| Total debt | — | — | — | — | — | 200 |
| Total liabilities | 820 | 813 | 784 | 761 | 734 | — |
| Total equity (incl. minority) | 6,400 | 5,901 | 7,096 | 6,590 | 7,174 | — |
| Retained earnings | 9,165 | 8,832 | 8,557 | 8,193 | 7,854 | — |